The amplified MYCN gene serves as an oncogenic driver in approximately 20% of high-risk pediatric neuroblastomas. Here we show that the family member c-MYC is a potent transforming gene in a separate subset of high-risk neuroblastoma cases (~10%), based on (i) its upregulation by focal enhancer amplification or genomic rearrangements leading to enhancer hijacking, and 
Introduction
Neuroblastoma is a tumor of the peripheral sympathetic nervous system (PSNS) that originates from neuroblasts of the migratory neural crest. It presents as high-risk disease in 40% of children, with half of these patients never achieving a durable response to available therapies (1) . Genomic amplification of the MYCN locus with elevated MYCN expression is associated with disseminated neuroblastoma and a poor prognosis (2) . Recent analysis of immunohistochemistry results indicates that high levels of c-MYC protein in neuroblastoma cells define a second subset of patients who also have a poor prognosis (3, 4) . In one of these studies, 20% of neuroblastomas had amplification of the MYCN gene and high levels of MYCN protein, while an additional 11% expressed high levels of c-MYC protein, implicating an independent subset of high-risk cases (4) . Previous studies have also suggested that the activity of c-MYC could serve an important role in facilitating the aggressiveness of MYCN non-amplified neuroblastoma (5, 6) . Hence, the observation of high levels of c-MYC expression in a subset of tumors without concomitant c-MYC amplification raises important questions regarding the genetic mechanisms through which c-MYC is activated in these cases.
Transcriptional dysregulation is a critical aspect of malignancy and is thought to have an essential role in the pathogenesis of many human cancers, including pediatric neuroblastoma (7, 8) . c-MYC and MYCN share the ability to sustain multiple pathways leading to malignancy, including a generalized elevation of gene expression levels within the cellular transcriptome, which overcomes rate-limiting steps in transformation (9, 10) . Most research and drug discovery efforts investigating high-risk neuroblastoma have focused on the subset of tumors with MYCN gene amplification, with much less is known about other high-risk subtypes of the disease. This is best illustrated by multiple studies showing that overexpression of MYCN as a transgene can drive neuroblastoma in vivo in both mice and zebrafish (11) (12) (13) , while it is still unknown whether To address key questions related to the potential role of c-MYC as a transforming oncogene in neuroblastoma, we tested its activity in a zebrafish model, focusing on several candidate genomic mechanisms that could lead to c-MYC activation in human tumors. Our findings show that when c-MYC is overexpressed as a transgene driven by the dopamine betahydroxylase (dßh) promoter, it initiates neuroblastoma in transgenic animals with a shorter latency and higher penetrance than seen with MYCN. Furthermore, whole genome sequencing of neuroblastoma cell lines and primary patient tumors lacking the amplified MYCN gene reveal that c-MYC is frequently activated through alternative genetic mechanisms. These include selection for either focal DNA amplification targeting enhancers distal to c-MYC coding sequences, or chromosomal translocations that aberrantly juxtapose super-enhancers from other highly expressed genes into topologically associating domains containing the c-MYC oncogene.
Together, these results firmly establish c-MYC as a transforming oncogene in a significant subset of cases of childhood neuroblastoma and elucidate at least some of the acquired genetic mechanisms that activate its aberrant expression. Whatever the mechanism, c-MYC does not act alone in transformation, but operates in concert with other acquired genetic and epigenetic abnormalities to produce the fully transformed phenotype.
Results

Expression of c-MYC and MYCN in neuroblastoma tumors and cell lines
Before investigating potential mechanisms for the activation of c-MYC in a subset of childhood neuroblastomas, we evaluated a dataset that includes whole transcriptome sequencing 
c-MYC transforms neuroblasts and drives neuroblastoma tumorigenesis in vivo
High-level expression in a subset of neuroblastomas does not by itself implicate c-MYC as an oncogenic driver, as it is well known that many genes lacking a role in transformation are highly expressed in diverse types of tumors. When the human MYCN coding sequences are expressed in the PSNS of mice or zebrafish, using the tyrosine hydroxylase or the dopaminebeta-hydroxylase promoter, the transgene readily initiates neuroblastoma (11) (12) (13) 16 described, we undertook these experiments in the zebrafish model system, generating transgenic zebrafish lines in which human c-MYC expression is driven by the zebrafish dopamine-betahydroxylase promoter (dβh:c-MYC; Fig. 2A ). To aid in isolating these lines, we coinjected dβh:c-MYC with a construct expressing mCherry driven by the same promoter (dβh:mCherry) that is specifically active within the developing PSNS, including the superior cervical and segmental sympathetic ganglia, postganglionic neurons, and chromaffin cells of the interrenal gland (IRG), the counterpart of the adrenal medulla in mammals (13) . Using this approach, we isolated two independently derived dβh:c-MYC; dβh:mCherry lines and crossed them to an independent line expressing a dβh:EGFP allele to provide consistent EGFP fluorescence intensity for visual and quantitative assays of tumor growth in vivo ( Fig. 2A ).
During development, PSNS cells derived from the embryonic neural crest migrate ventrally to form structures that give rise to the autonomic nervous system (17) . In our model systems, dβh:c-MYC and dβh:MYCN zebrafish lines both develop hyperplasia of neuroblasts in the PSNS by 7 days of life (Supplemental Fig. S3 ). The expansion of sympathoadrenal tissue in these models was closely monitored by weekly imaging from 4 to 7 weeks post-fertilization (wpf), and the area of EGFP fluorescence within the IRG was quantified. Minimal expansion of normal interrenal tissue was observed over this interval in control dβh:EGFP zebrafish (Fig. 2B ).
Most offspring of the dβh:MYCN fish showed evidence of neuroblast hyperplasia by 4 wpf; however, the MYCN-driven lesions regressed in size after 5 wpf, due to developmentally timed pro-apoptotic signaling (13) . By contrast, both dβh:c-MYC stable lines produced rapid and sustained expansion of IRG tissue (Fig. 2B ), due to reduced apoptosis and a higher proliferative To evaluate the transgenic lines for progression to neuroblastoma, we monitored tissue expansion by quantifying the area of EGFP fluorescence every 2 weeks beginning at 5 wpf, the age at which pro-apoptotic signaling must be overcome in dβh:MYCN fish to generate fully transformed neuroblastoma (13) . When performing tumor onset analysis, fluorescent tumor cell masses were clearly visible in the anterior abdomen of tumor-bearing fish, where the IRG tissue is located (Fig. 2C-D from the neural crest ( Fig. 2E) (18) . RNA-seq analysis demonstrated that both dβh:c-MYC and dβh:MYCN zebrafish tumors express moderate-to-high levels of genes preferentially expressed in human neuroblastoma compared to pheochromocytoma, another neural crest-derived tumor localized to the adrenal medulla (Supplemental Fig. S6 ). Additionally, genes highly expressed by human pheochromocytoma were expressed at low levels in the zebrafish tumors, supporting histologic evidence that the zebrafish tumors represent a faithful model of human neuroblastoma. 
Focal amplifications of noncoding elements downstream of c-MYC in neuroblastoma
Although our results in Figure 2 establish that c-MYC can induce highly penetrant neuroblastoma in the zebrafish, we are still left with the fact that unlike MYCN, the 8q24 chromosomal region containing the coding sequences of the c-MYC gene is generally not amplified in human neuroblastoma genomes (19, 20) . We therefore searched for other genomic abnormalities that could have been selected during transformation of the malignant clone to drive aberrantly elevated levels of c-MYC gene expression in human neuroblastoma. One mechanism sequence within a region of amplification frequently observed in lung cancer (21) , while another sample (PATEPF) had an amplified region matching one often seen in T-ALL and AML, which also becomes a large super-enhancer (22, 24) . In all likelihood, enhancer amplification downstream of c-MYC affects a region that already has active enhancer activity within the expanding premalignant clone. Thus, amplification of enhancer elements acts to increase the binding of transcription factors and the associated transcriptional apparatus dedicated to the upregulation of c-MYC expression, and thereby promotes malignant transformation within the abnormal cell clone.
Enhancer hijacking activates expression of c-MYC in a subset of human neuroblastomas
Analysis of WGS data from neuroblastoma cell lines identified chromosomal translocations in three of the four cell lines with high c-MYC expression. These included the t(7;8)(q33;q24) in SH-SY5Y and the t(4;8)(q34;q24) in NB69 and SKNAS cells (Fig. 4A ,B, Supplemental Table S2 and Supplemental Fig. S8 ). Of the 112 patients with either WGS or WES data, two had 8q translocations with breakpoints downstream of MYC, including one with t(6;8)(q25;q24) (PAMGZT), and another with t(4;8)(q34;q24) ( Fig. 4A,B (Fig 5A,C) . In both of these cell lines, the super-enhancer driving both HAND2/FBXO8 and c-MYC is the highest ranked enhancer by H3K27ac signal in the genome (Fig. 5B,D) . 
c-MYC gene promoter (blue parallelogram). This enhancer thus drives EXOC4 on the normal allele and also loops into close proximity with c-MYC on the translocated allele in this cell line, and it is also the highest ranked super-enhancer in SH-SY5Y cells by H3K27ac signal (Fig. 5F ).
This translocation was also detected by DNA PCR in the SKNSH cell line, from which SH-SY5Y was derived, as well as another SKNSH clone designated SHEP (Supplemental Fig. S8 ).
Based on ChIP-seq data, the EXOC4 super-enhancer has a much higher H3K27ac signal in SH- Since this lesion may act through haploinsufficiency for one or more genes within the minimally deleted region, identification of one or more of these genes could help to clarify the link between 11q-and high c-MYC expression in pediatric neuroblastoma (28) . 
Discussion
The MYCN oncogene has been closely associated with neuroblastoma since its discovery as a gene whose copy number is amplified many-fold in high risk forms of this disease (2) . The fact that only MYCN and never c-MYC itself is amplified in these cases led naturally to the hypothesis that MYCN is uniquely suited to mediate sympathetic neuroblast transformation. One The HAND2 gene is highly expressed in neural crest-derived cells and encodes a transcription factor that serves as an essential regulator of neuronal development (37) . Previous studies have demonstrated that the expression of key cell identity genes is regulated by cisregulatory elements, including super-enhancers, in a cell-type specific manner (31, 38) . In addition to chromosomal rearrangement, we show that amplification of endogenous enhancers downstream of c-MYC provides a separate mechanism of c-MYC upregulation in neuroblastoma (Fig. 3) . This mechanism, which frequently operates over considerable genomic distances, has recently been reported as an oncogenic mechanism in other tumor types (21, 22, 24) . Thus, by selecting for focal amplification of an active enhancer, tumor cells can 
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increase the quantity of active DNA-binding sites, allowing them to increase the density of interaction of transcription factors and other components of the transcriptional machinery with cis-regulatory elements, thereby leading to increased levels of gene expression (40, 41) .
Our studies in the zebrafish model system show that aberrant programmed expression of c-MYC in PSNS precursors is a highly effective driver of neuroblastomagenesis (Fig. 2) . These in vivo experiments suggest that in human neuroblastoma, aberrant expression of c-MYC in migratory neural crest cells is mediated by enhancer amplification or chromosomal translocations that hijack enhancers from developmentally active genes. As a result, immature sympathoadrenal cells overexpressing c-MYC, regardless of MYCN status, fail to acquire a terminally differentiated cell identity and continue to expand with unregulated growth properties.
We show that overexpression of either c-MYC or MYCN facilitates the malignant phenotype in neuroblastoma by blocking neuroblast differentiation, despite the actions of in vivo developmental cues that normally lead to rapid chromaffin cell differentiation as neuroblasts migrate to the adrenal medulla. In our transgenic model system, c-MYC is considerably more active than MYCN in transformation, apparently because of differences in the activity and posttranslational modification of these two proteins (42) . To date, the unique properties of MYCN have led to the development of drugs that inhibit the kinase-independent, stabilizing interaction of Aurora kinase A with MYCN, leading to the rapid degradation of MYCN and the death of cells addicted to this oncoprotein (33) . As additional unique aspects of these proteins are uncovered and drugs are discovered that target cells specifically dependent on either MYCN or c-MYC, it will become increasingly important to clearly delineate which of these proteins is mediating transformation in individual cases, enabling one to optimally exploit synthetic lethal opportunities for therapeutic gain. 
Methods
Zebrafish
Wildtype and transgenic zebrafish were maintained under standard aquaculture conditions at the Dana-Farber Cancer Institute. All experiments were approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #02-107.
DNA constructs and transgenic modeling
Cloning of the zebrafish dβh promoter (5.2 kb) and creation of dβh:EGFP and dβh:MYCN lines have been previously described (13) . Similarly, mCherry and human c-MYC cDNAs were PCR cloned into the pENTR223 vector, and dβh:mCherry and dβh:c-MYC constructs were individually assembled by Multisite Gateway cloning (Invitrogen). Using a co-injection strategy with I-SceI meganuclease, one-cell embryos were injected with DNA constructs and grown to adulthood. Primary injectants were screened for germline transmission, and stable lines were generated by outcrossing to the wild-type AB strain. (Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data) to evaluate tumor purity in each tumor (43) . Any tumor with an estimated purity of less than 70% was removed from further consideration.
Neuroblastoma cell culture
RNA sequencing analysis
Briefly, RNA-seq data were mapped to hg19 using an in-house-developed StrongArm method.
Fragments per kilobase per million mapped reads (FPKM) values were generated to measure gene expression levels in each tumor, based on the transcript model in GENCODE v19 using HTseq-count (44) . Quantile normalization was applied to the expression matrix, and the top 1000 most variably expressed genes were selected for hierarchical clustering with Ward's minimum variance method. We applied CICERO, a local assembly-based method relying on soft-clipped reads, to analyze the translocations identified from RNA-seq data, as previously described (45) .
Whole genome sequencing analysis
The WGS data of neuroblastoma cell lines were aligned to the reference human genome assembly GRCh37-lite using BWA (46) , and genomic translocation was analyzed with CREST (47) using tumor-only module. The WGS data of primary neuroblastoma tumors were derived from TARGET project under accession number of phs000467 (20) on NCBI dbGAP (https://www.ncbi.nlm.nih.gov/gap). We downloaded the SV results analyzed by CGI Cancer Sequencing service analytic pipeline v2 and applied an in-house developed filter pipeline.
Additional details are available in supplemental materials and methods.
ChIP-seq and genome-wide occupancy analysis
Research. Chromatin Immunoprecipitation (7) coupled with high-throughput DNA sequencing (ChIP-seq) was performed as previously described (48) . The antibody used for H3K27ac ChIP was purchased from Abcam (ab4729). For each ChIP, 10 µg of antibody was added to 3 ml of sonicated nuclear extract. Illumina sequencing, library construction and ChIP-seq analysis methods were previously described (48) . ChIP-seq datasets are available in GEO with identifiers shown in Table S3 .
Hi-C and data analysis
In situ Hi-C experiments were carried out as previous described (49) . Briefly, cell lines were cultured under recommended conditions to about 80% confluence. Five million cells were crosslinked with 1% formaldehyde for 10 min at room temperature, digested with 125 units of MboI, labeled by biotinylated nucleotides and proximity-ligated. After reverse crosslinking, ligated DNA was purified and sheared to 300-500bp. Ligation junctions were then pulled down with streptavidin beads and prepped as a standard Illumina library. Each library underwent 75-cycle paired-end sequencing on the Illumina HiSeq 4000. Raw sequence data were mapped and processed using Juicer v1.5 (50) with default parameters. The Hi-C data and MboI cut sites were mapped to hg19. The data matrices were further extracted from .hic files with the dump function from juicer tools, with a resolution of 5kb. The data were visualized with the Hi-C viewer under development through the Pediatric Cancer (PeCan) data portal (51) . Heatmap views of the data matrices were generated with 'pheatmap' package in R.
Statistical analysis
Statistical calculations were performed using Prism 7.01 (GraphPad). Linear regression analysis was used to determine the correlations presented in Fig. 1 . Kaplan-Meier methods and the log- rank test were applied to assess the rate of tumor onset in Fig. 1B, Fig. 2D Multivariate ANOVA analysis followed by two-tailed, unpaired t-tests with confidence intervals of 95% were used for the quantitative assays in Fig. 2 and Supplemental Figs. S3-S4 .
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